HC Wainwright Analysts Boost Earnings Estimates for AVXL

Anavex Life Sciences Corp. (NASDAQ:AVXL) – Equities research analysts at HC Wainwright raised their Q2 2026 earnings per share estimates for Anavex Life Sciences in a report issued on Tuesday, February 10th. HC Wainwright analyst R. Selvaraju now expects that the biotechnology company will post earnings per share of ($0.07) for the quarter, up from their previous estimate of ($0.11). HC Wainwright currently has a “Buy” rating and a $20.00 target price on the stock. The consensus estimate for Anavex Life Sciences’ current full-year earnings is ($0.69) per share. HC Wainwright also issued estimates for Anavex Life Sciences’ Q3 2026 earnings at ($0.08) EPS, Q4 2026 earnings at ($0.11) EPS and FY2026 earnings at ($0.33) EPS.

A number of other equities analysts also recently issued reports on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Anavex Life Sciences in a research report on Monday, December 29th. D. Boral Capital restated a “buy” rating and issued a $24.00 price objective on shares of Anavex Life Sciences in a report on Monday. Finally, Jones Trading lowered Anavex Life Sciences from a “buy” rating to a “hold” rating in a research report on Friday, October 24th. Two equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Anavex Life Sciences presently has an average rating of “Hold” and an average price target of $22.00.

Anavex Life Sciences Stock Performance

Anavex Life Sciences stock opened at $3.92 on Thursday. The company has a market cap of $363.27 million, a PE ratio of -8.52 and a beta of 1.21. Anavex Life Sciences has a fifty-two week low of $2.86 and a fifty-two week high of $13.99. The business’s 50-day simple moving average is $4.27 and its two-hundred day simple moving average is $6.92.

Anavex Life Sciences (NASDAQ:AVXL) last posted its quarterly earnings results on Monday, February 9th. The biotechnology company reported ($0.06) EPS for the quarter, beating the consensus estimate of ($0.10) by $0.04.

Hedge Funds Weigh In On Anavex Life Sciences

A number of institutional investors and hedge funds have recently made changes to their positions in AVXL. 180 Wealth Advisors LLC lifted its position in shares of Anavex Life Sciences by 213.4% during the 2nd quarter. 180 Wealth Advisors LLC now owns 44,050 shares of the biotechnology company’s stock valued at $406,000 after acquiring an additional 29,995 shares during the period. Nwam LLC increased its position in Anavex Life Sciences by 2.4% during the 2nd quarter. Nwam LLC now owns 1,024,479 shares of the biotechnology company’s stock worth $9,446,000 after purchasing an additional 24,128 shares in the last quarter. Intech Investment Management LLC raised its stake in Anavex Life Sciences by 51.4% in the 2nd quarter. Intech Investment Management LLC now owns 48,842 shares of the biotechnology company’s stock valued at $450,000 after purchasing an additional 16,589 shares during the last quarter. Stratos Wealth Partners LTD. purchased a new position in Anavex Life Sciences in the 2nd quarter valued at about $245,000. Finally, Geode Capital Management LLC boosted its stake in shares of Anavex Life Sciences by 2.8% during the 2nd quarter. Geode Capital Management LLC now owns 2,019,795 shares of the biotechnology company’s stock worth $18,624,000 after purchasing an additional 54,985 shares during the last quarter. 31.55% of the stock is owned by institutional investors and hedge funds.

More Anavex Life Sciences News

Here are the key news stories impacting Anavex Life Sciences this week:

• Positive Sentiment: HC Wainwright raised multiple 2026 EPS estimates (Q2, Q3, Q4 and FY2026) and now models FY2026 at a smaller loss, while reiterating a “Buy” rating and a $20.00 price target — a material positive for sentiment and valuation expectations. Read More.
• Positive Sentiment: Zacks upgraded Anavex to a Zacks Rank #2 (Buy), signaling growing optimism about its earnings prospects and placing additional buy‑side attention on the ticker. Read More.
• Positive Sentiment: HC Wainwright also published multi‑quarter and FY2027 EPS projections (new estimates for Q1–Q4 2027 and FY2027) alongside its coverage, reinforcing analyst engagement and a bullish $20 target. Read More.
• Neutral Sentiment: Analyst/sector comparison pieces note how AVXL is performing vs. medical peers year‑to‑date — useful for relative performance context but not an immediate catalyst. Read More.
• Neutral Sentiment: Short‑interest data reported for early February shows 0 shares and anomalous “NaN” increases — this appears to be a reporting/data issue rather than a real build in short pressure, so it’s not currently informative for direction. (Internal short‑interest entries 2/11–2/12)

About Anavex Life Sciences

Anavex Life Sciences Corp is a clinical‐stage biopharmaceutical company focused on the development of novel therapeutics for central nervous system (CNS) disorders. The company applies a proprietary drug discovery platform that targets sigma‐1 and muscarinic receptors to modulate cellular stress pathways and support neuronal function. Headquartered in New York City, Anavex is dedicated to advancing treatments for neurodegenerative and neurodevelopmental diseases with high unmet medical need.

The company’s lead product candidate, blarcamesine (ANAVEX2‐73), is a small‐molecule activator of the sigma‐1 receptor currently being evaluated in clinical trials for Alzheimer’s disease and Parkinson’s disease dementia.